Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437800 | 0.79 | NCF1 (0.34) | NCF1 | |
| SCHEMBL23674802 | 0.76 | NQO1 (0.34) | NQO1TSHRTDP1SMN1; SMN2MAPT | |
| SCHEMBL2885675 | 0.76 | NQO1 (0.34) | NQO1SMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL4463630 | 0.76 | MAPK8 (0.37) | NQO1SMN1; SMN2MAPTHTTALDH1A1 | |
| SCHEMBL17529638 | 0.74 | NQO1 (0.33) | NQO1L3MBTL1 | |
| SCHEMBL17529636 | 0.74 | ADORA2A (0.35) | NQO1SMN1; SMN2 | |
| SCHEMBL2888774 | 0.73 | GRM5 (0.36) | NQO1 | |
| SCHEMBL1273848 | 0.70 | GRM5 (0.39) | NQO1MAPTKDM4EALDH1A1 | |
| SCHEMBL17529613 | 0.70 | CTSS (0.36) | NQO1TSHRTDP1SMN1; SMN2MAPT | |
| SCHEMBL1638324 | 0.69 | NCF1 (0.38) | NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | claimed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | claimed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | claimed |
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | OXTR, AVPR2, AVPR1A | NCF1 2743/4885NQO1 410/4885MAT2A 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.